We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CCOLA:BISTCoca-Cola Icecek A.S. Analysis

Data as of 2026-09-08 - not real-time

TRY 79.30

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

At TRY 79.30, Coca-Cola Içecek Anonim Sirketi shows no decisive moving-average alignment, leaving the trend neutral. The last 30 days have lost 11.0%. RSI sits at 44.8, which reads as neutral, and MACD momentum is bullish. Watch TRY 75.20 as support and TRY 89.90 as the nearer resistance level.
Multiples put this in undervalued territory at a P/E of 11.4. Consensus targets land 39.8% above where the shares trade now. Revenue is growing at 5.7% on a 9.9% profit margin. The 1.81% dividend yield looks covered by current payout levels.
The composite risk read is 4/10, putting it in moderate territory. With 30-day volatility of 36.2%, a beta of 0.18 and a maximum drawdown of 18.6%, position sizing matters here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Short, medium and long-term reads agree on buy, with conviction of 7/10.

Top Market Events

Find out the direct holders, institutional holders and mutual fund holders for Coca-Cola Içecek Anonim Sirketi CCOLA.Seeking Alpha27dCoca-Cola Içecek Anonim Sirketi COLZF Q2 2026 Earnings Call TranscriptLadies and gentlemen, thank you...Seeking Alpha27dCoca-Cola Içecek Anonim Sirketi 2026 Q2 - Results - Earnings Call PresentationThe following slide deck...

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 6/10

Key Factors

  • Trading above the 200-day average of 74.50
  • MACD momentum is positive
  • 30-day price change of -11.0%

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Trading above the 200-day average of 74.50
  • Analyst targets imply +39.8% versus the current price
  • MACD momentum is positive

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Analyst targets imply +39.8% versus the current price
  • P/E ratio of 11.4
  • Return on equity of 22.4%

Key Metrics & Analysis

Financial Health

Revenue Growth5.70%
Profit Margin9.94%
P/E Ratio11.4
ROE22.43%
ROA9.19%
Debt/Equity55.47
P/B Ratio2.4
Op. Cash FlowTRY32.1B
Free Cash FlowTRY10.5B

Technical Analysis

TrendNeutral
RSI44.8
SupportTRY 75.20
ResistanceTRY 89.90
MA 20TRY 80.23
MA 50TRY 84.48
MA 200TRY 74.50
MACDBullish
VolumeDecreasing
Fear & Greed Index93.63

Valuation

Fair ValueTRY 50.01
Target PriceTRY 110.83
Upside/Downside39.76%
GradeUndervalued
TypeBlend
Dividend Yield1.81%

Risk Assessment

Beta0.18
Volatility36.16%
Sector RiskLow
Reg. RiskMedium
Geo RiskHigh
Currency RiskHigh
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.